e-learning
resources
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Utility of fractional exhaled nitric oxide suppression as a prediction tool for progression to biologic therapy
Claire A. Butler, Alan J. McMichael, Kirsty Honeyford, Louise Wright, Jayne Logan, Joshua Holmes, John Busby, Catherine E. Hanratty, Freda Yang, Steven J. Smith, Kirsty Murray, Rekha Chaudhuri, Liam G. Heaney
Source:
ERJ Open Res, 7 (3) 00273-2021; 10.1183/23120541.00273-2021
Journal Issue:
July
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Claire A. Butler, Alan J. McMichael, Kirsty Honeyford, Louise Wright, Jayne Logan, Joshua Holmes, John Busby, Catherine E. Hanratty, Freda Yang, Steven J. Smith, Kirsty Murray, Rekha Chaudhuri, Liam G. Heaney. Utility of fractional exhaled nitric oxide suppression as a prediction tool for progression to biologic therapy. ERJ Open Res, 7 (3) 00273-2021; 10.1183/23120541.00273-2021
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Investigation on the effectiveness of the Mostgraph and fractional exhaled nitric oxide measurement in chronic cough
Source: Annual Congress 2012 - Exhaled biomarkers in airway diseases
Year: 2012
Clinical utility of fractional exhaled nitric oxide in severe asthma management
Source: Eur Respir J, 55 (3) 1901633; 10.1183/13993003.01633-2019
Year: 2020
Clinical usefulness of fractional exhaled nitric oxide (FeNO) as a marker of long-term asthma control
Source: Annual Congress 2009 - Airway inflammation and asthma control
Year: 2009
Is exhaled nitric oxide measurement useful in clinical practice?
Source: ISSN=ISSN 1810-6838, ISBN=, page=185
Year: 2006
Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model
Source: Eur Respir J 2006; 28: 1236-1244
Year: 2006
Increased levels of fractional exhaled nitric oxide after chemotherapy for lung cancer. Ongoing study
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Usefulness of fractional exhaled nitric oxide (FeNO) as a marker of asthma control
Source: Annual Congress 2008 - Phenotyping of asthma and COPD
Year: 2008
Predicting response to corticosteroid in COPD using exhaled nitric oxide
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
Utility of fractional exhaled nitric oxide (FeNO) in assessing asthma control following inhaled corticosteroid treatment
Source: International Congress 2016 – Assessing lower airway inflammation with different tools
Year: 2016
Comparison of exhaled nitric oxide values measured by two offline methods or NO breath
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Accuracy of exhaled nitric oxide to predict a loss of asthma control in well-controlled patients
Source: Annual Congress 2010 - Biomarkers and Diagnosis of asthma and allergic respiratory diseases
Year: 2010
Exhaled nitric oxide as a biomarker in different COPD phenotypes
Source: International Congress 2018 – Biomarkers for evaluating COPD
Year: 2018
Value of exhaled nitric oxide in the evaluation of disease activity in sarcoidosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 174s
Year: 2002
The source of exhaled nitric oxide does not correlate with clinical markers in interstitial lung disease
Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease
Year: 2007
Fractional exhaled nitric oxide (FeNO) for an early diagnosis of asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 677s
Year: 2006
Extended measurement of exhaled nitric oxide in patients after lung transplantation
Source: Eur Respir J 2005; 26: Suppl. 49, 705s
Year: 2005
Fractional exhaled nitric oxide (FeNO) suppression with directly observed inhaled corticosteroid therapy: does it make a difference to patient outcomes?
Source: International Congress 2018 – Clinical and functional monitoring in airway disease
Year: 2018
Technical problems with measurements of biomarkers - exhaled nitric oxide
Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases
Year: 2017
The assessment of exhaled nitric oxide fraction in monitoring asthma control: How to raise the clinical relevance?
Source: Annual Congress 2010 - Cough, airway hyperresponsiveness and asthma control
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept